Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

CWP232291 (CWP291) is a small-molecule inhibitor of Wnt signaling that causes degradation of β-catenin via apoptosis induction through endoplasmic reticulum stress activation. This first-in-human, open-label, dose-escalation study to evaluate the safety, maximum tolerated dose (MTD), and preliminary...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Lee, Je-Hwan, Faderl, Stefan, Pagel, John M., Jung, Chul Won, Yoon, Sung-Soo, Pardanani, Animesh D., Becker, Pamela S., Lee, Howard, Choi, Jeongeun, Lee, Kyoungjune, Kim, Minkyoung, Cortes, Jorge E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7218422/
https://ncbi.nlm.nih.gov/pubmed/32396615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000757
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados